It was reported on September 25 that Novo Nordisk A/S (NYSE:NVO) has entered into an exclusive global license and collaboration agreement with Swedish drug delivery platform company Nanexa AB. The partnership centers on leveraging Nanexa's proprietary PharmaShell technology platform across up to five development programs focused on obesity, type 2 diabetes, and other cardiometabolic indications. The target outcome is formulating long-acting injectables capable of extending dosing intervals to monthly or quarterly schedules. Under the deal terms, Nanexa is eligible to receive total payments reaching €1.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。